Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1959 1
1964 3
1973 1
1974 1
1975 2
1976 1
1979 1
1980 4
1981 4
1982 2
1983 1
1984 4
1985 6
1986 7
1987 9
1988 9
1989 8
1990 7
1991 13
1992 13
1993 24
1994 30
1995 46
1996 53
1997 44
1998 68
1999 89
2000 79
2001 89
2002 104
2003 115
2004 143
2005 145
2006 219
2007 179
2008 229
2009 254
2010 305
2011 367
2012 425
2013 505
2014 560
2015 623
2016 635
2017 662
2018 737
2019 773
2020 953
2021 1163
2022 1018
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

9,631 results
Results by year
Filters applied: . Clear all
Page 1
Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O'Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilderäng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM; DELIVER Trial Committees and Investigators. Solomon SD, et al. Among authors: fang jc. N Engl J Med. 2022 Sep 22;387(12):1089-1098. doi: 10.1056/NEJMoa2206286. Epub 2022 Aug 27. N Engl J Med. 2022. PMID: 36027570 Clinical Trial.
Ultrasensitive Ribo-seq reveals translational landscapes during mammalian oocyte-to-embryo transition and pre-implantation development.
Xiong Z, Xu K, Lin Z, Kong F, Wang Q, Quan Y, Sha QQ, Li F, Zou Z, Liu L, Ji S, Chen Y, Zhang H, Fang J, Yu G, Liu B, Wang L, Wang H, Deng H, Yang X, Fan HY, Li L, Xie W. Xiong Z, et al. Among authors: fang j. Nat Cell Biol. 2022 Jun;24(6):968-980. doi: 10.1038/s41556-022-00928-6. Epub 2022 Jun 13. Nat Cell Biol. 2022. PMID: 35697785
Semi-Implantable Bioelectronics.
Fang J, Huang S, Liu F, He G, Li X, Huang X, Chen HJ, Xie X. Fang J, et al. Nanomicro Lett. 2022 May 28;14(1):125. doi: 10.1007/s40820-022-00818-4. Nanomicro Lett. 2022. PMID: 35633391 Free PMC article. Review.
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations.
Lu S, Dong X, Jian H, Chen J, Chen G, Sun Y, Ji Y, Wang Z, Shi J, Lu J, Chen S, Lv D, Zhang G, Liu C, Li J, Yu X, Lin Z, Yu Z, Wang Z, Cui J, Xu X, Fang J, Feng J, Xu Z, Ma R, Hu J, Yang N, Zhou X, Wu X, Hu C, Zhang Z, Lu Y, Hu Y, Jiang L, Wang Q, Guo R, Zhou J, Li B, Hu C, Tong W, Zhang H, Ma L, Chen Y, Jie Z, Yao Y, Zhang L, Jie W, Li W, Xiong J, Ye X, Duan J, Yang H, Sun M, Sun C, Wei H, Li C, Ali SM, Miller VA, Wu Q. Lu S, et al. Among authors: fang j. J Clin Oncol. 2022 Sep 20;40(27):3162-3171. doi: 10.1200/JCO.21.02641. Epub 2022 May 17. J Clin Oncol. 2022. PMID: 35580297 Free PMC article. Clinical Trial.
IL27 Signaling Serves as an Immunologic Checkpoint for Innate Cytotoxic Cells to Promote Hepatocellular Carcinoma.
Aghayev T, Mazitova AM, Fang JR, Peshkova IO, Rausch M, Hung M, White KF, Masia R, Titerina EK, Fatkhullina AR, Cousineau I, Turcotte S, Zhigarev D, Marchenko A, Khoziainova S, Makhov P, Tan YF, Kossenkov AV, Wiest DL, Stagg J, Wang XW, Campbell KS, Dzutsev AK, Trinchieri G, Hill JA, Grivennikov SI, Koltsova EK. Aghayev T, et al. Among authors: fang jr. Cancer Discov. 2022 Aug 5;12(8):1960-1983. doi: 10.1158/2159-8290.CD-20-1628. Cancer Discov. 2022. PMID: 35723626
When AIE meets enzymes.
Feng G, Liao S, Liu Y, Zhang H, Luo X, Zhou X, Fang J. Feng G, et al. Among authors: fang j. Analyst. 2022 Sep 12;147(18):3958-3973. doi: 10.1039/d2an00679k. Analyst. 2022. PMID: 35929552 Review.
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial.
Lu S, Wu L, Jian H, Chen Y, Wang Q, Fang J, Wang Z, Hu Y, Sun M, Han L, Miao L, Ding C, Cui J, Li B, Pan Y, Li X, Ye F, Liu A, Wang K, Cang S, Zhou H, Sun X, Ferry D, Lin Y, Wang S, Zhang W, Zhang C. Lu S, et al. Among authors: fang j. Lancet Oncol. 2022 Sep;23(9):1167-1179. doi: 10.1016/S1470-2045(22)00382-5. Epub 2022 Jul 28. Lancet Oncol. 2022. PMID: 35908558 Clinical Trial.
Novel Insights into miR-944 in Cancer.
Shen J, Wang Q, Liang C, Su X, Ke Y, Mao Y, Fang J, Duan S. Shen J, et al. Among authors: fang j. Cancers (Basel). 2022 Aug 31;14(17):4232. doi: 10.3390/cancers14174232. Cancers (Basel). 2022. PMID: 36077769 Free PMC article. Review.
9,631 results